中文 | English     

PD-1/PD-L1 antibody pharmacological efficacy test using B-NDG mice

2017-05-25 16:08:35.0

B-NDG mice(NOD-Prkdcscid Il2rgtm1/Bcgen), independently developed by Biocytogen, are highly immunodeficient. Transplantation of human tumor cells into B-NDG mice and accompanying human antibody treatments can verify drug pharmacological efficacies. This experimental system is reliable because it uses both human cell lines and a humanized immune environment.

 

PD-1 antibody pharmacological efficacy experiments were performed after human-derived tumor U-87 MG cell lines were transplanted into B-NDG mice. Our results suggest that the TGI (tumor growth inhibition) in B-NDG mice treated with PD-1 antibody for 15 days is 52.55% (p<0.05), significantly higher when compared to NOD-scid mice. Therefore, B-NDG mice are superior than NOD-scid mice in tumor immune related in vivo pharmacological efficacy trials.



图片.png


Fig 1. Efficacy test of a human PD-1 antibody on human glioblastoma U-87 MG cells. U-87 cells were inoculated into the right hypochondriac region of B-NDG mice and grouped when the tumor sizes were about 30mm(n=6). PBMCs from volunteers after CD3 antibody stimulation were injected into tumor tissues, and different antibodies were administered by i.p. injection three times a week for two weeks. The TGI (tumor growth inhibition) 15 days after treatment was 52.55% (p0.05). This inhibitory effect is remarkable.


图片.png

Fig 2. Efficacy test of a human PD-1 antibody on human glioblastoma U-87 MG cells. U-87 cells were inoculated into the right hypochondriac region of NOD-scid mice and grouped when the tumor sizes were about 40mm(n=7). PBMCs from volunteers after CD3 antibody stimulation were injected into tumor tissues, and different antibodies were administered by i.p. injection three times a week for two weeks. No inhibitory effect from PD-1 antibody treatment was detected.


Copyright © BIOCYTOGEN LLC. 2017 All Rights Reserved.